drugset / Trial / NCT06194500

A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

NCT06194500

Phase 1 Completed 18 enrolled Eli Lilly and Company
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 (\[14C\] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive \[14C\] LY3549492 given into a vein. The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath. The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.

Timeline

Start
2024-01-03
Primary completion
2024-02-15
Completion
2024-02-15

Drugs

EvaluationDrugModalityDoseRoute
Subject LY3549492 Unknown Oral

Indications

No indication recorded.